Русский
Clinical significance of determining nitric oxide synthesis regulators in chronic obstructive pulmonary disease in comorbidity with arterial hypertension
DOI: https://dx.doi.org/10.18565/therapy.2024.6.8-14
Kanatbekova Zh.K., Shakhanov A.V., Uryasyev O.M., Nikiforov A.A.
Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia
The aim: to study the clinical significance of determination of L-arginine, arginase-1 and asymmetric dimethylarginine (ADMA) in blood plasma of COPD patients in conditions of cardiovascular comorbidity.
Material and methods. 133 individuals aged 40 to 64 years (mean age 56 [52; 60] years) were involved in the study. All the participants were divided into 2 groups: the main group included 109 patients with COPD, control group included 24 practically healthy persons. The groups were comparable by gender (p = 0.341) and age (p = 0.055), as well as by smoking status: all subjects had a history of tobacco smoking and were active smokers. Determination of L-arginine, arginase-1 and ADMA levels in blood plasma was made by means of enzyme immunoassay methodic using Cloud-Clone Corp. laboratory kits (China).
Results. Presence of COPD has a significant effect on the level of arginase-1: corresponding indexes were 1.40 [0.90; 5.90] ng/ml in the main group versus 1.07 [0.57; 1.75] ng/ml in control one (p = 0.013). There was also a tendency towards the influence of the disease on ADMA content, which was significantly lower in the group of patients with COPD: 98.8 [21.1; 114.5] versus 104.3 [96.3; 109.7] ng/ ml in the control group (p = 0.053). ADMA level in COPD patients with mild (79.05 [42.60; 129.15]), moderate (101.15 [92.08; 108.78]) and severe (109,80 [87,40; 179,80]) severity of bronchial obstruction was significantly higher than in patients with extremely severe (10.70 [10.40; 11.18]) burden of the disease (p = 0.007). Concentration of arginase-1 was higher in the group of COPD with concomitant arterial hypertension: 2.11 [0.99; 8.9] versus 1.10 [0.90; 1.2] ng/ml in the COPD group without hypertension and 1.07 [0.57; 1.75] ng/ml in control group (p < 0.01). The level of L-arginine was statistically significantly lower in the COPD group with concomitant arterial hypertension comparatively to COPD group without hypertension and the control group: 9.6 [7.10; 12.30] versus 11.2 [9.28; 15.03] µg/ml and 10.95 [9.97; 11.83] µg/ml, respectively (p = 0.029).
Conclusion. The levels of arginase-1 and ADMA are associated with the presence of COPD in a patient. The levels of ADMA, L-arginine, arginase-1 and the ADMA/L-arginine ratio observed in the blood are associated with the characteristics of the clinical course of COPD. The presence of COPD and hypertension comorbidity in a patient also significantly affects the content of arginase-1 and L-arginine.
Literature
1. Yach D., Hawkes C., Gould C.L., Hofman K.J. The Global Burden of Chronic Diseases. JAMA. 2004; 291(21): 2616. https://doi.org/10.1001/jama.291.21.2616. PMID: 15173153. 2. André S., Conde B., Fragoso E. et al. COPD and cardiovascular disease. Pulmonology. 2019; 25(3): 168–76. https://doi.org/10.1016/j.pulmoe.2018.09.006. PMID: 30527374. 3. Brown J.P., Martinez C.H. Chronic obstructive pulmonary disease comorbidities. Curr Opin Pulm Med. 2016; 22(2): 113–18. https://doi.org/10.1097/MCP.0000000000000241. PMID: 26814720. 4. Christenson S.A., Smith B.M., Bafadhel M., Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022; 399(10342): 2227–42. https://doi.org/10.1016/S0140-6736(22)00470-6. PMID: 35533707. 5. Wang H., Ye X., Zhang Y., Ling S. Global, regional, and national burden of chronic obstructive pulmonary disease from 1990 to 2019. Front Physiol. 2022; 13: 925132. https://doi.org/10.3389/fphys.2022.925132. PMID: 36017339. PMCID: PMC9396373. 6. Zinellu A., Mangoni A.A. Arginine, Transsulfuration, and folic acid pathway metabolomics in chronic obstructive pulmonary disease: A Systematic review and meta-analysis. Cells. 2023; 12(17): 2180. https://doi.org/10.3390/cells12172180. PMID: 37681911. PMCID: PMC10486395. 7. Brandsma C., Van den Berge M., Hackett T. et al. Recent advances in chronic obstructive pulmonary disease pathogenesis: From disease mechanisms to precision medicine. J Pathol. 2020; 250(5): 624–35. https://doi.org/10.1002/path.5364. PMID: 31691283. PMCID: PMC7216938. 8. Moller M.N., Rios N., Trujillo M. et al. Detection and quantification of nitric oxide–derived oxidants in biological systems. J Biol Chem. 2019; 294(40): 14776–802. https://doi.org/10.1074/jbc.REV119.006136. PMID: 31409645. PMCID: PMC6779446. 9. Mangoni A.A., Rodionov R.N., McEvoy M. et al. New horizons in arginine metabolism, ageing and chronic disease states. Age Ageing. 2019; 48(6): 776–82. https://doi.org/10.1093/ageing/afz083. PMID: 31268522. 10. Ruzsics I., Nagy L., Keki S. et al. L-arginine pathway in COPD patients with acute exacerbation: A new potential biomarker. COPD. 2016; 13(2): 139–45. https://doi.org/10.3109/15412555.2015.1045973. PMID: 26514682. 11. Chen Y., Xu X., Sheng M. et al. PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy. Exp Eye Res. 2009; 89(6): 1028–34. https://doi.org/10.1016/j.exer.2009.09.004. PMID: 19748504. 12. Urban M.H., Eickhoff P., Funk G.C. et al. Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD. Int J COPD. 2017; 12: 169–76. https://doi.org/10.2147/COPD.S118596. PMID: 28115840. PMCID: PMC5221539. 13. Scrimini S., Pons J., Agustí A. et al. Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. Respir Med. 2013; 107(12): 1895–903. https://doi.org/10.1016/j.rmed.2013.08.002. PMID: 23993707. 14. Tajti G., Gesztelyi R., Pak K. et al. Positive correlation of airway resistance and serum asymmetric dimethylarginine level in COPD patients with systemic markers of low-grade inflammation. Int J COPD. 2017: 12: 873–84. https://doi.org/10.2147/COPD.S127373. PMID: 28352168. PMCID: PMC5358999. 15. Pera T., Zuidhof A.B., Smit M. et al. Arginase inhibition prevents inflammation and remodeling in a Guinea Pig model of chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2014; 349(2): 229–38. https://doi.org/10.1124/jpet.113.210138. PMID: 24563530.
About the Autors
Zharkynay K. Kanatbekova, postgraduate student of the Department of faculty therapy named after Professor V.Ya. Garmash, Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia. Address: 390026, Ryazan, 9 Vysokovoltnaya St.
E-mail: janya_kanatbekova@mail.ru
ORCID: https://orcid.org/0000-0003-3314-760X
Anton V. Shakhanov, MD, PhD (Medicine), associate professor, associate professor of the Department of faculty therapy named after Professor V.Ya. Garmash, Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia. Address: 390026, Ryazan, 9 Vysokovoltnaya St.
E-mail: shakhanovav@gmail.com
ORCID: https://orcid.org/0000-0002-5706-9418
Oleg M. Uryasyev, MD, Dr.Sci. (Medicine), professor, head of the Department of faculty therapy named after Professor V.Ya. Garmash, Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia. Address: 390026, Ryazan, 9 Vysokovoltnaya St.
E-mail: uryasev08@yandex.ru
ORCID: https://orcid.org/0000-0001-8693-4696
Alexander A. Nikiforov, MD, PhD (Medicine), associate professor, head of the Central research laboratory of Academician I.P. Pavlov Ryazan State Medical University of the Ministry of Healthcare of Russia. Address: 390026, Ryazan, 9 Vysokovoltnaya St.
E-mail: a.nikiforov@rzgmu.ru
ORCID: https://orcid.org/0000-0002-7364-7687
Similar Articles
